Overview
Bloomberg Law quoted Vishal Gupta in a June 19 article titled "Rush for Generic Go-Ahead on Novel Drugs Roils Pharma Industry." The article discusses how multiple generic drugmakers are seeking to be first to file applications for cheaper versions of a brand-name drug, spurring more litigation for brand-name drugmakers that must then defend their patents.
"When you have 30 challenges on a patent, then there are potentially 30 different shots on goal to invalidate the patents," Gupta says. "If all relevant patents are found invalid, then at least all first-filing generic companies could come to the market at the same time. You would immediately get substantial competition in that event."
The full article can be read at Bloomberg Law.
